{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-26-002371","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.819424+00:00","generated_at":"2026-05-14T21:53:45.143661+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit","bullets":["Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.","R&D spending rose to $1.0M from $0.4M, driven by INM-901 Alzheimer's program costs.","Cash and equivalents decreased to $5.2M as of March 31, 2026 from $10.8M at June 30, 2025.","INM-901 showed anti-neuroinflammatory effects in human 3D brain organoid models of Alzheimer's disease.","Board approved wind down of BayMedica commercial operations, expected completion by June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-002371","json":"https://secwatch.observer/filing/0001062993-26-002371.json","markdown":"https://secwatch.observer/filing/0001062993-26-002371.md","text":"https://secwatch.observer/filing/0001062993-26-002371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326002371/0001062993-26-002371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326002371/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:53:45.143661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}